Table 2.

Outcome measurements among patients with atopic dermatitis successfully treated with methotrexate or dupilumab

	Methotrexate (n = 6)			Dupilumab (n = 11)
	At start	At follow-upa	p value	At start	At follow-upa	p value
	Mean (range)	Mean (range)		Mean (range)	Mean (range)
EASIb	16.8 (7.4–30.3)	2.8 (0–6.8)	0.028*	28.6 (6.2–50)	5.2 (0.3–17.5)	0.003*
POEMc	17.2 (6–27)	6.7 (0–21)	0.075	19.9 (11–28)	4.9 (0–16)	0.005*
VASc	5.7 (0.7–8.5)	2.4 (0.1–7.8)	0.028*	6.3 (0.4–10)	1.1 (0.1–3.4)	0.007*
DLQIb	18.5 (10–26)	8.7 (1–15)	0.028*	10.2 (1–25)	1.6 (0–6)	0.005*
MADRSc	14.6 (13–18)	7.3 (3–12)	0.034*	13.7 (1–50)	3.9 (0–10)	0.028*
Weightd (kg)	74.8 (60–102)	70.5 (57.7–85)	0.075	87.1 (58–123)	93.6 (65.5–136.4)	0.003*

Abbreviations: EASI Eczema area severity score, POEM Patient-oriented eczema measure, VAS Visual analogue scale, DLQI Dermatology life quality index, MADRS Montgomery-Åsberg depression rating scale

Significant differences marked with *. P values calculated using Wilcoxon matched-pairs sign-rank tests

^aFollow-up after 12 months of treatment. Some patients had shorter follow-up and some variables were missing at 12 months, but collected at 6 or 9 months of follow-up

^bFollow-up at 12 months (n = 16), at 9 months (n = 1)

^cFollow-up at 12 months (n = 16), missing value at follow-up (n = 1)

^dFollow-up at 12 months (n = 15), at 9 months (n = 1), at 6 months (n = 1)